CNBCLean R·
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
Read at CNBC →
Business · 1 sources covering this
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/061d378480b6b5cd495ce06a8d7de7282b85ba02" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports"></iframe>
